Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades

Inclusion Criteria: * Locally advanced squamous cell carcinoma of the head and neck and participation in the HICARE-phase-IV-trial * Cetuximab-induced painful rhagades, i.e. SUPO Score 2-3 (see Figure 2) * Compliance to the photo documentation * Ability of subject to understand character and individual consequences of the clinical trial * Written informed consent Exclusion Criteria: * Cetuximab-induced rhagades without any pain, i.e. SUPO Score 1 * Cetuximab-induced rhagades, SUPO Score 4, i.e. superinfection of the rhagades * Patients not being enrolled in the HICARE trial * Substance misuse, psychoactive substance abuse or psychological/social conditions leading to a decreased patients' compliance with possible bad influence to the results of the study * Known allergic reaction to ethyl-2-cyanoacrylate (ECA)